Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 29;13(7):1268.
doi: 10.3390/v13071268.

The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies

Affiliations
Review

The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies

Dan Liu et al. Viruses. .

Abstract

Increasing rates of infection by antibiotic resistant bacteria have led to a resurgence of interest in bacteriophage (phage) therapy. Several phage therapy studies in animals and humans have been completed over the last two decades. We conducted a systematic review of safety and toxicity data associated with phage therapy in both animals and humans reported in English language publications from 2008-2021. Overall, 69 publications met our eligibility criteria including 20 animal studies, 35 clinical case reports or case series, and 14 clinical trials. After summarizing safety and toxicity data from these publications, we discuss potential approaches to optimize safety and toxicity monitoring with the therapeutic use of phage moving forward. In our systematic review of the literature, we found some adverse events associated with phage therapy, but serious events were extremely rare. Comprehensive and standardized reporting of potential toxicities associated with phage therapy has generally been lacking in the published literature. Structured safety and tolerability endpoints are necessary when phages are administered as anti-infective therapeutics.

Keywords: animal models; clinical trials; immune activation; phage therapy; safety and toxicity.

PubMed Disclaimer

Conflict of interest statement

G.A.S. received grants and has an equity and royalty-bearing know-how agreement with Adaptive Phage Therapeutics (APT). The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Search strategy.

References

    1. Alanis A.J. Resistance to antibiotics: Are we in the post-antibiotic era? Arch. Med. Res. 2005;36:697–705. doi: 10.1016/j.arcmed.2005.06.009. - DOI - PubMed
    1. Kortright K.E., Chan B.K., Koff J.L., Turner P.E. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe. 2019;25:219–232. doi: 10.1016/j.chom.2019.01.014. - DOI - PubMed
    1. Gordillo Altamirano F.L., Barr J.J. Phage Therapy in the Postantibiotic Era. Clin. Microbiol Rev. 2019;32:e00066-18. doi: 10.1128/CMR.00066-18. - DOI - PMC - PubMed
    1. Keen E.C. A century of phage research: Bacteriophages and the shaping of modern biology. Bioessays. 2015;37:6–9. doi: 10.1002/bies.201400152. - DOI - PMC - PubMed
    1. Wittebole X., De Roock S., Opal S.M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5:226–235. doi: 10.4161/viru.25991. - DOI - PMC - PubMed

Publication types